| | April 20166CIOReviewCIOReviewNOVEMBER 20 - 2015Managing EditorJeevan GeorgeEditorial StaffVisualizersStephen ThomasArun ThomasAlex D' SouzaAnwesha BoseLinda RebeccaRonald Magnus Allwyn JoeJudy CristinPhilip ArcherSandeepa MajumdarDDoS SpecialReshaping the Future of PharmaEditorialCIOReviewAPRIL - 07 - 2016Managing EditorJeevan GeorgeEditorial StaffVisualizersStephen ThomasArun ThomasPharma and Life Sciences SpecialWith its major investments in research, reliance on complex chemistry, and sophisticated understanding of human biology, the pharmaceuticals industry is generally regarded as a technologically advanced sector. However, the innovation within the industry today is facing a troubled and uncertain future. Patents for many blockbuster drugs--some of them, which have created billions of dollars in revenue--have expired; health systems are no longer willing to pay what they used to for pharmaceuticals; and regulators are asking companies to produce and deliver more complex product portfolios at a lower cost, while continuing to meet stringent quality requirements. This calls for a transformation within the industry--one that is powered by technology.There are many building blocks for this transformation. According to PwC, one of the major steps pharmaceutical companies need to take is to create better connectivity between different parts of their value chains. Today many systems within the architecture of pharma companies--R&D, manufacturing or CRM--is in the stand-alone form. Bringing connectivity into these systems will help companies add flexibility into manufacturing, reduce costs, respond to regulations, and bridge the gap between R&D and manufacturing.Further, the interconnected systems will help companies link the feedback from patients directly to the development and manufacturing process. Feedback from clients and suppliers provide opportunities for product improvement and cost reductions. This is important at a time when the pharmaceutical companies need to demonstrate that their brand adds value to patients, while offering a package of products and health services that the market not only wants, but is willing to pay a premium for. Another step towards this transformation is replacing the current labor intensive methods of drug manufacturing to a more, refined one. This requires the batch processes to be replaced with new technologies like continuous manufacturing, which makes the entire process efficient, less expensive, and more environmentally friendly. Even more, with the first 3D printed drug to receive approval from the U.S. Food and Drug Administration began its shipping this week, we can expect more technologies disrupting this area.Apropos this scenario, our aim with this edition is to help companies discover best-of-breed technology solution providers who can help pharmaceutical companies on their journey towards transformation. This edition blends thought-leadership from subject matter experts with real stories on what selected vendors are doing for their clients.Let us know what you think.Jeevan GeorgeManaging Editoreditor@cioreview.comMatthew JacobSusan AndersonAlex D'Souza Kyle SummersCopyright © 2016 CIOReview. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Mailing AddressCIOReview44790 S. Grimmer Blvd Suite 202, Fremont, CA 94538T:510.402.1463, F:510-894-8405 APRIL - 07 - 2016, Vol 05 SE 20 Published by CIOReview To subscribe to CIOReviewVisit www.cioreview.com CIOReviewSalesT:510.565.7626David Edwarddavid@cioreview.com
< Page 5 | Page 7 >